Tenet Healthcare Co. (NYSE:THC) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. cut its holdings in shares of Tenet Healthcare Co. (NYSE:THC) by 9.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,761 shares of the company’s stock after selling 387 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Tenet Healthcare were worth $284,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in THC. GAMMA Investing LLC purchased a new stake in shares of Tenet Healthcare in the 4th quarter valued at approximately $52,000. Sunbelt Securities Inc. purchased a new stake in shares of Tenet Healthcare in the 3rd quarter valued at approximately $67,000. FinTrust Capital Advisors LLC grew its position in shares of Tenet Healthcare by 108.6% in the 4th quarter. FinTrust Capital Advisors LLC now owns 897 shares of the company’s stock valued at $68,000 after buying an additional 467 shares during the last quarter. USA Financial Formulas purchased a new position in shares of Tenet Healthcare in the 3rd quarter valued at $92,000. Finally, Bellevue Group AG grew its position in shares of Tenet Healthcare by 106.7% in the 4th quarter. Bellevue Group AG now owns 1,447 shares of the company’s stock valued at $109,000 after buying an additional 747 shares during the last quarter. 95.44% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

THC has been the topic of a number of recent analyst reports. Mizuho reaffirmed a “buy” rating and issued a $130.00 target price (up from $118.00) on shares of Tenet Healthcare in a research report on Wednesday, May 1st. Truist Financial reaffirmed a “buy” rating and issued a $130.00 target price (up from $120.00) on shares of Tenet Healthcare in a research report on Wednesday, May 1st. Baird R W upgraded shares of Tenet Healthcare to a “strong-buy” rating in a research note on Thursday, May 30th. Barclays increased their price target on shares of Tenet Healthcare from $113.00 to $147.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. Finally, Wolfe Research upgraded shares of Tenet Healthcare from a “peer perform” rating to an “outperform” rating and set a $122.00 price target for the company in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $120.41.

Insider Buying and Selling at Tenet Healthcare

In other Tenet Healthcare news, Director Christopher S. Lynch sold 10,861 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $133.83, for a total transaction of $1,453,527.63. Following the completion of the transaction, the director now directly owns 14,759 shares in the company, valued at approximately $1,975,196.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Tenet Healthcare news, Director Richard W. Fisher sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $123.20, for a total transaction of $308,000.00. Following the completion of the transaction, the director now directly owns 17,627 shares in the company, valued at approximately $2,171,646.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher S. Lynch sold 10,861 shares of Tenet Healthcare stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $133.83, for a total transaction of $1,453,527.63. Following the sale, the director now owns 14,759 shares of the company’s stock, valued at $1,975,196.97. The disclosure for this sale can be found here. In the last three months, insiders sold 24,691 shares of company stock worth $3,117,909. 0.93% of the stock is owned by corporate insiders.

Tenet Healthcare Stock Up 0.6 %

Shares of NYSE THC opened at $135.69 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.44 and a debt-to-equity ratio of 2.58. Tenet Healthcare Co. has a 52 week low of $51.04 and a 52 week high of $142.35. The firm has a 50-day moving average price of $125.34 and a 200 day moving average price of $101.69. The stock has a market capitalization of $13.25 billion, a price-to-earnings ratio of 5.27, a price-to-earnings-growth ratio of 1.39 and a beta of 2.12.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $1.45 by $1.77. Tenet Healthcare had a net margin of 12.53% and a return on equity of 26.76%. The firm had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter last year, the business earned $1.42 earnings per share. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. Equities research analysts anticipate that Tenet Healthcare Co. will post 8.55 EPS for the current fiscal year.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.